- Home
- MGRX vs APRE Comparison
MGRX vs APRE Comparison
Compare MGRX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | APRE |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.4M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MGRX | APRE |
|---|---|---|
| Price | $0.35 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | ★ 10.0M | 216.2K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.55 |
| 52 Week High | $2.88 | $2.22 |
Technical Indicators
Market Signals| Indicator | MGRX | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 45.75 |
| Support Level | $0.32 | $0.55 |
| Resistance Level | $0.47 | $0.98 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 30.11 | 48.08 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.